Krystal Mitchell, APRN
Nurse Practitioner · Wichita, KSNPI 1356956890
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,305 of the $12,598 with a category attached, or 89.7%. It is spread thinly across 20 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,135, 3.9 times the $1,309 reported in 2021. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 647 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$906
- plus $4K from 14 others
What the payments were for
- Consulting fees$1,28010%
- Food & beverage$11,30590%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 103 | $1,901 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $1,726 |
| E.r. Squibb & Sons, L.L.C. | 9 | $1,572 |
| Johnson & Johnson | 78 | $1,381 |
| Neurocrine Biosciences, Inc. | 74 | $1,029 |
| AbbVie | 63 | $906 |
| Teva Pharmaceuticals USA, Inc. | 49 | $870 |
| Alkermes, Inc. | 49 | $803 |
| Vanda Pharmaceuticals Inc. | 37 | $766 |
| Lundbeck LLC | 30 | $462 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $302 |
| Sunovion Pharmaceuticals Inc. | 17 | $222 |
| Axsome Therapeutics, Inc. | 11 | $200 |
| Indivior Inc. | 11 | $161 |
| Eisai Inc. | 4 | $87 |
| Supernus Pharmaceuticals, Inc. | 4 | $66 |
| Merck | 4 | $55 |
| Avanir Pharmaceuticals, Inc. | 3 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Biogen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$723
- REXULTI$477
- INVEGA SUSTENNA$474
- VRAYLAR$101
How this compares
$12,598 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 17 | $168,828 |
| RexultiBrexpiprazole | 79 | $108,605 |
| VraylarCariprazine Hcl | 73 | $107,537 |
| AustedoDeutetrabenazine | 23 | $76,039 |
| Invega SustennaPaliperidone Palmitate | 15 | $48,948 |
| CaplytaLumateperone Tosylate | 26 | $43,737 |
| Abilify MaintenaAripiprazole | 15 | $40,001 |
| Risperdal ConstaRisperidone Microspheres | 27 | $33,375 |
| Lurasidone Hcl | 73 | $23,787 |
| Aripiprazole | 109 | $7,847 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,308 |
| Paliperidone ErPaliperidone | 56 | $5,946 |
| Fluphenazine Decanoate | 26 | $2,804 |
| Buspirone Hcl | 245 | $2,312 |
| Quetiapine Fumarate | 186 | $2,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $1,381 | $251,15159 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,901 | $148,60694 claims |
| AbbVieVraylar | $906 | $107,53773 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $870 | $76,03923 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,726 | $43,73726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $302 | $7,30815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Wichita
- Constance JacobWichita$65K
- Catherine PowellWichita$50K
- Darine JamaleddineWichita$15K
- Jolene GrotheWichita$11K
- Christina StantonWichita$11K
- Sarah RookerWichita$10K
- Ayman HamadWichita$9K
- Amanda MogoiWichita$9K
- Jill AugustineWichita$8K
- Rebecca WernliWichita$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.